‘Now is the time to push for greater investment in CGM tech,’ report finds 

EDINBURGH, Scotland, and SAN DIEGO – Tech, not medicine, is the future of care for Type 2 diabetes patients, according to a new report from Dexcom. 

Fifty-two percent of health care professionals ranked access to continuous glucose monitors and education as having the potential to positively help people with Type 2 manage their condition in the next 10 years compared with 30% who cited better or more effective medications. 

“With policymakers increasingly focused on digital transformation in health care, now is the time to push for greater investment in CGM technology as a core component of Type 2 management,” said Adrian Gut, senior director of international access, advocacy and value at Dexcom. “Enhancing CGM accessibility is crucial to tackling the Type 2 crisis. By ensuring equitable access to this life-changing technology, we can empower people with Type 2 to take control of their diabetes management, improve their quality of life and reduce complications. This will significantly improve public health outcomes and reduce long-term healthcare costs. Now is the time to make a transformative impact on the lives of millions.” 

The report, “"Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East,” surveyed more than 2,500 individuals with Type 2 diabetes and health care professionals from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the U.K. 

Other findings in the report include: 

• 77% of people with Type 2 diabetes who had not used CGM expected it to improve the lives of those with Type 2 compared to 93% of people with Type 2 diabetes who had used CGM and agreed it had a positive impact 
• Half of all HCPs felt CGM should be the standard of care for people with Type 2 diabetes whether they were using insulin to manage the condition or not. 96% of HCPs agreed those using multiple daily injections of insulin should receive CGM and 86% agreed those relying on basal insulin should be offered CGM. 
• HCPs see funding constraints (35%) and narrow inclusion criteria (20%) as the primary barriers to CGM adoption. Twenty-two percent of HCPs believe increasing education for people with Type 2 diabetes could drive higher CGM usage. 

Read the full Dexcom State of Type 2 report at https://bit.ly/DexcomATTD2025.